Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures ...

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26 ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

By Ana Swanson The White House on Thursday clarified that China faced a minimum tariff rate of 145 percent on all imports to the United States. A day earlier, President Trump had said that he was ...

The US hiked tariffs on Chinese goods to 145 per cent, prompting China to retaliate ... Tata Motors at 4.37 per cent, Cipla at 4.20 per cent, and JSW Steel at 4.10 per cent. Asian Paint (-0. ...

Benchmark Indian indices surged on April 11, with Sensex rising over 1,300 points and Nifty 50 up nearly 2 percent following a relief rally on US President Trump's 90-day pause on tariffs, which is ...

A total of 293 stocks traded in the upper circuit, and 145 in the lower circuit ... Stock market live updates today: Cipla receives USFDA approval for Abbreviated New Drug Application for ...